Benefits
Stress reduction in under 30 days
12-week randomized double-blind placebo-controlled trial in adults with mild-to-moderate stress. 125 mg/day Zenroot produced a significant decrease in Perceived Stress Scale scores in less than 30 days vs placebo, supported by objective skin-response measurement alongside the subjective scale.
Sleep quality improvement (12-week trial)
The same trial documented statistically significant improvements in sleep quality by day 28 vs both baseline and placebo, sustained through the 12-week protocol. Sleep mechanism consistent with ashwagandha's broader adaptogenic profile — reducing nighttime cortisol and supporting calmer sleep onset.
2.1× higher bioavailability vs 600 mg 5% reference
Randomized double-blind single-dose crossover bioavailability study in healthy adults under fasting. 125 mg Zenroot achieved 2.1× higher total withanolide plasma absorption vs a 600 mg ashwagandha 5%-withanolide reference, and 1.3× higher vs a 500 mg 10% reference. Established the low-dose efficacy rationale measurably.
Mood and occasional anxiety improvements
12-week trial outcomes included statistically significant improvements in mood state and severity of occasional anxiety symptoms vs placebo. Consistent with ashwagandha's traditional Ayurvedic use as a calming adaptogen. Mechanism likely involves HPA axis modulation and GABAergic activity.
Root-only sourcing for regulatory safety
European regulators have flagged concerns about ashwagandha aerial parts (leaves), which have higher withaferin A content potentially associated with rare hepatic adverse events. Root-only sourcing (the traditional Ayurvedic preparation) reduces this regulatory and safety concern, making Zenroot more suitable for European markets and long-term use.
Low-dose convenience for novel formats
The 125 mg low-dose advantage enables formulation in gummies, functional shots, ready-to-drink beverages, and other formats where higher mg doses wouldn't fit. Competing ashwagandha extracts at 500-600 mg are challenging for these formats. Excellent organoleptic profile (bland taste, dissolution) supports beverage applications.
Mechanism of action
HPA axis modulation
Ashwagandha withanolides modulate the hypothalamic-pituitary-adrenal axis, reducing baseline cortisol and dampening cortisol response to stressors. Multiple ashwagandha trials show 15-30% reductions in serum cortisol after 8-12 weeks. The HPA modulation underlies both stress and sleep benefits.
GABAergic activity
Withanolides bind to GABA-A receptors with modulatory effects similar in kind (but milder) to benzodiazepines. This GABAergic activity contributes to the calming nootropic profile — anxiolytic effects without sedation at typical clinical doses.
Enhanced bioavailability (Zenroot-specific)
OmniActive's proprietary extraction and standardization process delivers withanolides in a form with improved absorption — documented as 2.1× higher plasma withanolide exposure vs 600 mg 5%-withanolide reference. The mechanism appears to involve the natural withanolide profile and matrix rather than added bioavailability enhancers.
Antioxidant and anti-inflammatory effects
Withanolides have direct antioxidant activity and modulate inflammatory pathways (NF-κB, NLRP3 inflammasome). Chronic stress drives oxidative stress and inflammation; ashwagandha's antioxidant/anti-inflammatory effects complement its HPA axis modulation for broader stress resilience support.
Clinical trials
Randomized double-blind single-dose crossover comparative oral bioavailability study in 20 healthy adults under fasting conditions.
20 healthy adults
Randomized double-blind single-dose crossover comparative oral bioavailability study in 20 healthy adults under fasting conditions. Three arms: Zenroot 125 mg (1.5% withanolides), reference 600 mg (5% withanolides), reference 500 mg (10% withanolides). Plasma withanolide measurements at multiple time points over 24 hours. Outcome: Zenroot 125 mg achieved 2.1× higher absorption than the 600 mg 5% reference and 1.3× higher than the 500 mg 10% reference.
12-week randomized double-blind placebo-controlled trial in 90 adults aged 18-55 with mild-to-moderate stress. Intervention: 125 mg/day Zenroot or placebo.
90 adults aged 18-55 with mild-to-moderate stress
12-week randomized double-blind placebo-controlled trial in 90 adults aged 18-55 with mild-to-moderate stress. Intervention: 125 mg/day Zenroot or placebo. Outcomes: significant decrease in Perceived Stress Scale and Mindfield eSense Skin Response in under 30 days; sleep quality improvement by day 28 vs baseline and placebo; improvements in mood state and severity of occasional anxiety symptoms over 12 weeks. Conducted at Bengaluru Neuro Center, Santosh Hospital.